1. Home
  2. INLX vs ATOS Comparison

INLX vs ATOS Comparison

Compare INLX & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Intellinetics Inc.

INLX

Intellinetics Inc.

N/A

Current Price

$7.30

Market Cap

35.9M

Sector

Technology

ML Signal

N/A

Logo Atossa Therapeutics Inc.

ATOS

Atossa Therapeutics Inc.

HOLD

Current Price

$5.09

Market Cap

36.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INLX
ATOS
Founded
1996
2009
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.9M
36.2M
IPO Year
2013
2010

Fundamental Metrics

Financial Performance
Metric
INLX
ATOS
Price
$7.30
$5.09
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$31.67
AVG Volume (30 Days)
1.4K
76.4K
Earning Date
03-26-2026
03-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
16.67
EPS
N/A
N/A
Revenue
$11,336.00
$1,758.00
Revenue This Year
N/A
N/A
Revenue Next Year
$15.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.42
$0.53
52 Week High
$15.72
$7.56

Technical Indicators

Market Signals
Indicator
INLX
ATOS
Relative Strength Index (RSI) 34.57 63.03
Support Level N/A $0.68
Resistance Level $8.29 $7.56
Average True Range (ATR) 0.07 0.39
MACD -0.02 -0.04
Stochastic Oscillator 0.00 66.79

Price Performance

Historical Comparison
INLX
ATOS

About INLX Intellinetics Inc.

Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Document Management and Document Conversion. The Document Management segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Conversion offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Conversion Segment.

About ATOS Atossa Therapeutics Inc.

Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Share on Social Networks: